{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T05:03:35Z","timestamp":1748495015032,"version":"3.37.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malignant pleural mesothelioma (MPM) is a rare and deadly malignancy with an extremely poor prognosis. The median overall survival (OS) of this disease is 12\u201318\u00a0months. However, the oncogenic driver mutations of MPM are rarely understood, and the targeted therapy for it is still under investigation. In this report, we describe a case of MPM with <jats:italic>CD74-ROS1<\/jats:italic> fusion who obtains complete and durable response after receiving crizotinib. By the time of submission, the progression-free survival (PFS) with crizotinib has been 6.0\u00a0years, and the patient has survived for 7.6\u00a0years. Currently, he is still in complete remission (CR). To the best of our knowledge, this case represents the first report of <jats:italic>CD74-ROS1<\/jats:italic> fusion identified in MPM. Meanwhile, it is also the first report of complete and long-term response to crizotinib in a patient with MPM positive for <jats:italic>CD74-ROS1<\/jats:italic> fusion. This case report might contribute to the tumorigenesis and targeted therapy of this deadly disease.<\/jats:p>","DOI":"10.1007\/s00432-022-04076-0","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T06:02:22Z","timestamp":1654063342000},"page":"2561-2566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion"],"prefix":"10.1007","volume":"148","author":[{"given":"Xuehua","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxing","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erhong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunyou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beifang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4368-4380","authenticated-orcid":false,"given":"Weiming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"issue":"8","key":"4076_CR1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","volume":"30","author":"K Bergethon","year":"2012","unstructured":"Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Iafrate AJ (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30(8):863\u2013870. https:\/\/doi.org\/10.1200\/JCO.2011.35.6345","journal-title":"J Clin Oncol"},{"issue":"7","key":"4076_CR2","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/ijc.33447","volume":"148","author":"RSP Huang","year":"2021","unstructured":"Huang RSP, Haberberger J, Sokol E, Schrock AB, Danziger N, Madison R, Ross JS (2021) Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases. Int J Cancer 148(7):1778\u20131788. https:\/\/doi.org\/10.1002\/ijc.33447","journal-title":"Int J Cancer"},{"issue":"24","key":"4076_CR3","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.1158\/1078-0432.CCR-19-0994","volume":"25","author":"L Landi","year":"2019","unstructured":"Landi L, Chiari R, Tiseo M, D\u2019Inca F, Dazzi C, Chella A, Cappuzzo F (2019) Crizotinib in MET-deregulated or ROS1-rearranged pretreated non-small cell lung cancer (METROS): a phase II, prospective, multicenter two-arms trial. Clin Cancer Res 25(24):7312\u20137319. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0994","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4076_CR4","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/JCO.2014.58.3302","volume":"33","author":"J Mazieres","year":"2015","unstructured":"Mazieres J, Zalcman G, Crino L, Biondani P, Barlesi F, Filleron T, Gautschi O (2015) Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol 33(9):992\u2013999. https:\/\/doi.org\/10.1200\/JCO.2014.58.3302","journal-title":"J Clin Oncol"},{"issue":"7","key":"4076_CR5","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jtho.2019.03.020","volume":"14","author":"S Michels","year":"2019","unstructured":"Michels S, Massuti B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Wolf J (2019) Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): a European phase II clinical trial. J Thorac Oncol 14(7):1266\u20131276. https:\/\/doi.org\/10.1016\/j.jtho.2019.03.020","journal-title":"J Thorac Oncol"},{"issue":"3","key":"4076_CR6","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","volume":"19","author":"A Scherpereel","year":"2018","unstructured":"Scherpereel A, Wallyn F, Albelda SM, Munck C (2018) Novel therapies for malignant pleural mesothelioma. Lancet Oncol 19(3):e161\u2013e172. https:\/\/doi.org\/10.1016\/S1470-2045(18)30100-1","journal-title":"Lancet Oncol"},{"issue":"7","key":"4076_CR7","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","volume":"30","author":"AT Shaw","year":"2019","unstructured":"Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Ou SI (2019) Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol 30(7):1121\u20131126. https:\/\/doi.org\/10.1093\/annonc\/mdz131","journal-title":"Ann Oncol"},{"issue":"14","key":"4076_CR8","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1200\/JCO.2017.75.5587","volume":"36","author":"YL Wu","year":"2018","unstructured":"Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T, Goto K (2018) Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol 36(14):1405\u20131411. https:\/\/doi.org\/10.1200\/JCO.2017.75.5587","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04076-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04076-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04076-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T03:30:42Z","timestamp":1659583842000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04076-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["4076"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04076-0","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"17 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Erhong Meng, Shunyou Wang and Beifang Niu are employees at ChosenMed Technology. The remaining authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This report was approved by the Ethics Committee of the First Hospital of Putian City. The study has been performed in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written consent was obtained from the patient for the participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of clinical details and images.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}